COLUMBUS, Ohio, and CAMBRIDGE, Mass., Mar. 24, 2025 /PRNewswire/ —Sermonix Pharmaceuticals, a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast cancers (mBC), and Regor Therapeutics Group, a clinical-stage global biopharmaceutical company, today announced a strategic collaboration to optimize Regor’s proprietary, cutting-edge rCARD™ (Regor Computer Accelerated Rational Discovery) platform for identification of novel targets and therapeutics that fulfill unmet patient clinical needs and preferences in the breast oncology arena.

The partnership aims to develop efficacious and well-tolerated treatments for advanced metastatic breast cancer. It will unite the key core competencies of both organizations to leverage expertise from early discovery through preclinical, clinical, and commercial launch, resulting in treatments that deliver on the promise of fulfilling on efficacy but also developing therapies with tolerability and quality of life profiles that are aligned with patient priorities and concerns.

Read the full article on prnewswire.com